These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Some important ophthalmological aspects of endocrine orbitopathy. Goder GJ Radiobiol Radiother (Berl); 1987; 28(5):539-41. PubMed ID: 3441596 [No Abstract] [Full Text] [Related]
4. [A clinical analysis of Graves' ophthalmopathy and ophthalmic Graves' disease]. Liao ZQ Zhonghua Yan Ke Za Zhi; 1992 Jul; 28(4):236-9. PubMed ID: 1299571 [TBL] [Abstract][Full Text] [Related]
5. Clever is not enough: NOSPECS is form in search of function. Gorman CA Thyroid; 1991; 1(4):353-5. PubMed ID: 1841733 [TBL] [Abstract][Full Text] [Related]
8. Why the NOSPECS classification of Graves' eye disease should be abandoned, with suggestions for the characterization of this disease. Frueh BR Thyroid; 1992; 2(1):85-8. PubMed ID: 1525574 [TBL] [Abstract][Full Text] [Related]
9. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves' disease. Burggasser G; Hurtl I; Hauff W; Lukas J; Greifeneder M; Heydari B; Thaler A; Wedrich A; Virgolini I J Nucl Med; 2003 Oct; 44(10):1547-55. PubMed ID: 14530465 [TBL] [Abstract][Full Text] [Related]
10. Prevention of graves' orbitopathy: early diagnosis of thyroid-associated orbitopathy in Graves' disease. Mourits MP Orbit; 2008; 27(6):399-400. PubMed ID: 19085291 [No Abstract] [Full Text] [Related]
11. Long-term results of surgical treatment in Graves' disease orbitopathy. Is there a correlation between the extent of thyroidectomy and the course of orbithopathy? Maurer E; Dănilă R; Dominguez E; Osei-Agymang T; Zielke A; Hassan I Chirurgia (Bucur); 2008; 103(3):291-5. PubMed ID: 18717277 [TBL] [Abstract][Full Text] [Related]
12. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Prummel MF; Bakker A; Wiersinga WM; Baldeschi L; Mourits MP; Kendall-Taylor P; Perros P; Neoh C; Dickinson AJ; Lazarus JH; Lane CM; Heufelder AE; Kahaly GJ; Pitz S; Orgiazzi J; Hullo A; Pinchera A; Marcocci C; Sartini MS; Rocchi R; Nardi M; Krassas GE; Halkias A Eur J Endocrinol; 2003 May; 148(5):491-5. PubMed ID: 12720530 [TBL] [Abstract][Full Text] [Related]
17. Natural history of graves' orbitopathy after treatment. Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471 [TBL] [Abstract][Full Text] [Related]
18. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy. Laurberg P; Berman DC; Andersen S; Bülow Pedersen I Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677 [TBL] [Abstract][Full Text] [Related]
19. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study. Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054 [TBL] [Abstract][Full Text] [Related]
20. [New perspectives for the diagnosis and prognosis of Graves' disease]. Tatulashvili S; Baudry C; Sadoul JL; Bihan H Ann Endocrinol (Paris); 2018 Sep; 79 Suppl 1():S31-S39. PubMed ID: 30213303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]